TRABID overexpression in prostate cancer patient samples and TRABID overexpression-mediated HR activity inhibition and chromosomal instability prompted us to determine whether overexpressed TRABID enables synthetic lethality to PARP inhibitor in prostate cancer cells. Here, ZRANB1 is linked to prostate carcinoma.